TICKERNERD
Menu
ANTXANTXHealthcare · Biotechnology

ANTX Stock Forecast: AN2 Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$5.99
+0.17% on the day

The 2 Wall Street analysts covering AN2 Therapeutics, Inc. hold a median 12-month price target of $9 — +50.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$226.0M
Ticker Nerd rank
74 / 100
Median analyst target
$9.00
Analysts covering
2
Total return, dividends reinvested
1W
+1.0%
1M
+25.8%
YTD
+425.4%
1Y
+467.8%
From 52W high
−4.6%
From 52W low
+481.6%
$1.03
$6.28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AN2 Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Revisions
79
Size
68
Value
65
Quality
62
Volatility
53
Accruals
47
Issuance
34
Growth
30

Momentum (99): The shares have been drifting up relative to others.

Growth (30): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26ANTXHigh $9.00Median $9.00Low $9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $9.00Median $9.00High $9.00

The green dot is the last close — the median target sits +50.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 July 2026GuggenheimInitiatesBuy$9.00
14 May 2026Leerink PartnersUpgradeOutperform$9.00
14 May 2026Leerink PartnersUpgradeOutperform—
5 May 2025JMP SecuritiesMaintainsMarket Outperform—
26 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
25 Feb 2025Citizens Capital MarketsReiteratesMarket Outperform—
3 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
19 Nov 2024JMP SecuritiesReiteratesMarket Outperform—
18 Nov 2024TD CowenDowngradeHold—
9 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
3 July 2024Leerink PartnersUpgradeOutperform—
16 May 2024Evercore ISI GroupMaintainsIn-Line—
2 Apr 2024JMP SecuritiesUpgradeMarket Outperform—
1 Apr 2024OppenheimerReiteratesPerform—
13 Feb 2024Leerink PartnersDowngradeMarket Perform—
12 Feb 2024Evercore ISI GroupDowngradeIn-Line—
12 Feb 2024JMP SecuritiesDowngradeMarket Perform—
12 Feb 2024OppenheimerDowngradePerform—
4 Jan 2024JMP SecuritiesInitiatesMarket Outperform—
30 Mar 2023OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ANTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

AN2 Therapeutics, Inc. (ANTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.2×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
−3.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−50.1%

Higher than 21% of US stocks

Return on assets
−30.8%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ANTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANTXAN2 Therapeutics, Inc.$226.0M
74
ALECAlector, Inc.$213.9M
41
NERVMinerva Neurosciences, Inc.$213.4M
31
TNXPTonix Pharmaceuticals Holding Corp.$218.0M
21
IVVDInvivyd, Inc.$212.4M
19
IMUXImmunic, Inc.$218.8M
40
RNAAtrium Therapeutics, Inc.$219.7M
6

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AN2 Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANTX news & analysis

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Business Wire · 11 Aug 2026positive

AN2 Therapeutics reported its financial results for the second quarter ended June 30, 2026, along with recent business and scientific highlights. The company stated it expects to have three Phase 2 programs underway by the end of this year, all aimed at addressing major unmet needs, with near-term focus on advancing start-up activities.

Why it matters — AN2 Therapeutics watchers would care because the company's stated plan to have three Phase 2 programs underway by year-end signals expansion of its clinical pipeline based on its boron chemistry platform.

FAQ

Frequently asked questions about ANTX stock

What is the ANTX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering AN2 Therapeutics, Inc. have a median 12-month price target of $9, with estimates ranging from $9 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANTX stock a buy right now?

Of the 2 analysts covering AN2 Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AN2 Therapeutics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANTX?

As at 15 Aug 2026, AN2 Therapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will ANTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +50.3% from the last close, and Ticker Nerd's factor model ranks AN2 Therapeutics, Inc. 74 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANTX stock forecast for 2030?

No analyst covering AN2 Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $9 over the next 12 months.

How has ANTX stock performed over the past year?

AN2 Therapeutics, Inc. returned +467.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AN2 Therapeutics, Inc. do?

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its proprietary boron chemistry platform.

What is the latest news on ANTX?

The most recent item we track (Business Wire, 11 Aug 2026): "AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights". AN2 Therapeutics reported its financial results for the second quarter ended June 30, 2026, along with recent business and scientific highlights. The company stated it expects to have three Phase 2 programs underway by the end of this year, all aimed at addressing major unmet needs, with near-term focus on advancing start-up activities.

Company

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its proprietary boron chemistry platform. The company advances treatments for serious infectious diseases with high unmet needs, including non-tuberculous mycobacterial lung disease, acute melioidosis, chronic Chagas disease, and M. abscessus lung disease. Its lead candidate, epetraborole, is an oral therapy in phase 3 clinical trials for non-tuberculous mycobacterial lung disease and under investigation for additional indications such as polycythemia vera and melioidosis. AN2 Therapeutics also develops AN2-502998, a boron-based compound in early clinical stages for chronic Chagas disease, alongside research programs targeting tuberculosis, oncology, and other infectious diseases. Through strategic collaborations, including with GSK for tuberculosis therapies, the company leverages its platform to create potentially transformative medicines. Headquartered in Menlo Park, California, and incorporated in 2017, AN2 Therapeutics emphasizes global health initiatives to deliver impactful drugs that improve patient outcomes in rare and chronic conditions.

CEO Mr. Eric E. Easom · 21 employees · United States · https://www.an2therapeutics.com